US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Class II · Moderate risk Terminated

Minoxidil 0.75%

Reason Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Pharmacy Innovations D-0189-2023
Class II · Moderate risk Terminated

Methylcobalamin 1MG/ML

Reason Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Pharmacy Innovations D-0188-2023
Class II · Moderate risk Terminated

Hydroxocobalamin 25MG/ML

Reason Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Pharmacy Innovations D-0187-2023
Class II · Moderate risk Terminated

Chlorpheniramine/Hyoscyamine

Reason Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Pharmacy Innovations D-0186-2023
Class II · Moderate risk Terminated

Dutasteride 0.1%

Reason Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Pharmacy Innovations D-0185-2023
Class II · Moderate risk Terminated

Epi-Caine

Reason CGMP Deviations: Raw material recalled by repackager, due to discoloration.

Pine Pharmaceuticals, LLC NDC 69194-0948-1 D-0130-2023
Class II · Moderate risk Completed

Glycopyrrolate Tablets

Reason Failed impurities/degradation specifications: Out of specification for unknown impurities.

Avkare LLC NDC 50268-363-15 D-0091-2023
Class II · Moderate risk Terminated

Rifampin Capsules USP

Reason Failed Impurities/Degradations Specifications

Amerisource Health Services LLC NDC 60687-586-01 D-0165-2023
Class II · Moderate risk Terminated

Rifampin Capsules

Reason Failed Impurities/Degradation specifications

RemedyRepack Inc. NDC 68180-0659-07 D-0098-2023
Class II · Moderate risk Terminated

Ganciclovir for Injection

Reason Labeling: Label mix-up - one vial was mislabeled as Cladribine Injection 10mg/mL inside a 10-count carton of Ganciclovir 500 mg.

Hikma Pharmaceuticals USA Inc. NDC 0143-9299-01 D-0090-2023
Class II · Moderate risk Ongoing

Glycopyrrolate Tablets

Reason Failed Impurities/Degradation Specifications

Aurolife Pharma, LLC NDC 13107-014-01 D-0087-2023
Class II · Moderate risk Terminated

Rifampin Capsules USP

Reason Failed Impurities/Degradation Specifications: Failure observed in related substance testing during long term stability study.

Lupin Pharmaceuticals Inc. NDC 68180-659-06 D-0100-2023
Class II · Moderate risk Terminated

Menastil

Reason cGMP Deviations

Atlantic Management Resources Ltd. NDC 66233-711-01 D-0084-2023
Class II · Moderate risk Terminated

ProSirona

Reason cGMP Deviations

Atlantic Management Resources Ltd. NDC 66233-712-01 D-0083-2023
Class II · Moderate risk Terminated

Neuroquell

Reason cGMP Deviations

Atlantic Management Resources Ltd. D-0082-2023
Class II · Moderate risk Terminated

Neuroquell Plus

Reason cGMP Deviations

Atlantic Management Resources Ltd. D-0081-2023
Class II · Moderate risk Completed

Alcohol Antiseptic 80% Topical Solution Hand Sanitizer

Reason CGMP Deviations: Impurities of acetal and acetaldehyde were discovered in the product in excess of allowed limits.

NCH Life Sciences LLC NDC 55533-524-02 D-0092-2023
Class II · Moderate risk Terminated

Thiamine Hydrochloride 3000 mg/30 mL

Reason Presence of Particulate Matter: Presence of foreign substances were reported in vials at the pharmacy.

McGuff Compounding Pharmacy Services, Inc. D-0267-2023